• Contact Us
Friday, May 27, 2022
Health Business
Advertisement
  • Home
  • News
    Ebola vaccine approved by FDA

    Covid: Fourth-dose jab trial shows good boost

    Microbiology diagnostics: Removing the Kenyan antimicrobial resistance blindfold

    Microbiology diagnostics: Removing the Kenyan antimicrobial resistance blindfold

    Food apps and online gaming driving obesity – WHO

    Food apps and online gaming driving obesity – WHO

    Hepatitis detected in nearly 300 children worldwide

    Hepatitis detected in nearly 300 children worldwide

  • Events
  • Private
    • KHF
    • Providers
  • Government
    • Medical Research
    • Politics & Policy
    • Regulation, Enforcement & Compliance
  • Finance
  • Tech
  • Epaper
  • Videos
  • Home
  • News
    Ebola vaccine approved by FDA

    Covid: Fourth-dose jab trial shows good boost

    Microbiology diagnostics: Removing the Kenyan antimicrobial resistance blindfold

    Microbiology diagnostics: Removing the Kenyan antimicrobial resistance blindfold

    Food apps and online gaming driving obesity – WHO

    Food apps and online gaming driving obesity – WHO

    Hepatitis detected in nearly 300 children worldwide

    Hepatitis detected in nearly 300 children worldwide

  • Events
  • Private
    • KHF
    • Providers
  • Government
    • Medical Research
    • Politics & Policy
    • Regulation, Enforcement & Compliance
  • Finance
  • Tech
  • Epaper
  • Videos
No Result
View All Result
Health Business
No Result
View All Result

New drugs work against the many strains of hepatitis C found in African countries

by Health Business
May 31, 2021
in News, Public Health
0
New drugs work against the many strains of hepatitis C found in African countries
Share This:

John McLauchlan, University of Glasgow

Around the world, 71 million people have been infected with the hepatitis C virus. The primary route of infection is through direct contact with another person’s blood. This means the virus can be transmitted in a number of ways, including intravenous drug use, tattooing, contaminated blood or blood products and surgical procedures.

Infection with this virus can lead to severe disease of the liver. Annually, there are about 400,000 deaths resulting from the effects of infection. If the body fails to naturally clear the virus within a few weeks of initial infection, then it can remain in the liver for decades. This may gradually lead to cirrhosis or liver cancer. In addition, those carrying the virus are often stigmatised, which may prevent people from coming forward for testing or treatment.

There’s no vaccine available to prevent infection. For more than 20 years, the only available treatment for infection relied on weekly injections of interferon combined with an oral drug called ribavirin. But this treatment was only successful in curing between 40% and 65% of those who were infected. And it frequently led to adverse side effects (such as fatigue, nausea and depression) that could continue after treatment stopped.

Within the past few years, a new series of drugs called direct-acting antivirals have been developed, which give a much higher rate of curing infection (exceeding 90%). These drugs only need to be taken orally, and have very few side effects. They also require a relatively short course of treatment for 12 weeks – compared to as long as 48 weeks for interferon-based therapy.

The hepatitis C virus has evolved in different human populations for hundreds or even thousands of years. Over time the virus has become extremely genetically diverse. But the number of strains is limited in high-income countries where the new drugs are in use and known to be effective.

The question we sought to answer in our recent research was whether direct-acting antivirals would be effective in areas where many more strains are found, which are primarily low-income countries. Our findings show that these drugs would indeed be effective against most strains. This information is invaluable to countries with scarce treatment resources. More effective use of such resources ultimately will save more lives.

Testing new treatments

Our study examined a large cohort of people born in 32 African countries but living in the UK, who were infected with strains of the hepatitis C virus found in their country of birth.

Most of this group had received direct-acting antivirals to treat their infection. So we were able to combine an analysis of the genetic diversity of the hepatitis C virus strains with which they were infected and whether treatment had been successful.

Overall, we showed that direct-acting antivirals were very effective against almost all the hepatitis C virus strains found across Africa. There were two strains that did not respond well to some treatment combinations. But re-treating people with a different set of direct-acting antivirals led to successful cure in most cases.

This study is important because low-income countries face numerous challenges with hepatitis C virus infection.

In Africa, more than 10 million people are infected with the virus. Most countries have a limited infrastructure to diagnose infection, treat those who are infected and confirm that treatment has been successful. In addition, the cost of direct-acting antivirals places an economic burden on many countries.

Therefore, it is important to catalogue all possible diverse strains of the virus and determine whether they respond to direct-acting antivirals treatment. The main problem with hepatitis C virus diversity is that some strains can have natural resistance to treatment. Since confirming successful treatment of infection is an added burden for low-income countries, it is crucial that the most appropriate direct-acting antivirals combinations are used in settings where potentially resistant strains may circulate.

Improving treatment in Africa

Our study shows that more potent direct-acting antiviral drugs would work successfully in countries where numerous different strains are found, including those with strains that are resistant to some of the less potent direct-acting antivirals combinations.

Hence our study feeds into the information needed to select the best suite of drugs for curing hepatitis C in low-income environments. Moreover, since the World Health Organisation has mandated the global elimination of hepatitis C by 2030, our study contributes to that goal by confirming the crucial role that direct-acting antivirals will play.The Conversation

John McLauchlan, Professor of Viral Hepatitis, University of Glasgow

This article is republished from The Conversation under a Creative Commons license. Read the original article.

Share This:
Previous Post

Covid: Russia starts vaccinating animals

Next Post

World Bank chief says it's vital to speed up vaccine supply chain

Related Posts

Ebola vaccine approved by FDA
News

Covid: Fourth-dose jab trial shows good boost

May 12, 2022
Microbiology diagnostics: Removing the Kenyan antimicrobial resistance blindfold
News

Microbiology diagnostics: Removing the Kenyan antimicrobial resistance blindfold

May 12, 2022
Food apps and online gaming driving obesity – WHO
News

Food apps and online gaming driving obesity – WHO

May 5, 2022
Next Post
World Bank chief says it’s vital to speed up vaccine supply chain

World Bank chief says it's vital to speed up vaccine supply chain

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

No Result
View All Result

Follow Us

Most Read

  • Microbiology diagnostics: Removing the Kenyan antimicrobial resistance blindfold

    Microbiology diagnostics: Removing the Kenyan antimicrobial resistance blindfold

    0 shares
    Share 0 Tweet 0
  • Understanding of low back pain with recent evidence

    0 shares
    Share 0 Tweet 0
  • Menopause: what are the symptoms and why does it happen?

    0 shares
    Share 0 Tweet 0
Health Business

Health Business contains need-to-know features, news and case studies that explain the administrative and commercial issues affecting healthcare and hospital management. Health Business supports several high profile exhibitions - coverage of which is always timed for maximum impact. Regular topics include ICT, Finance/Funding, Facilities Management, Security, Health & Safety. Contributors range from government ministers through to top-level health administrators and association chairs.

Top Stories

Ebola vaccine approved by FDA

Covid: Fourth-dose jab trial shows good boost

May 12, 2022
Microbiology diagnostics: Removing the Kenyan antimicrobial resistance blindfold

Microbiology diagnostics: Removing the Kenyan antimicrobial resistance blindfold

May 12, 2022
Food apps and online gaming driving obesity – WHO

Food apps and online gaming driving obesity – WHO

May 5, 2022

Interests

  • Events
  • Finance
  • Government
  • Magazines
  • Medical Research
  • News
  • Politics & Policy
  • Providers
  • Public Health
  • Regulation, Enforcement & Compliance
  • Technology
  • Videos

Follow Us

  • Contact Us

© 2019 | Site by Mark & Ryse.

No Result
View All Result
  • Home
  • News
  • Events
  • Private
    • KHF
    • Providers
  • Government
    • Medical Research
    • Politics & Policy
    • Regulation, Enforcement & Compliance
  • Finance
  • Tech
  • Epaper
  • Videos

© 2019 | Site by Mark & Ryse.